Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCPNASDAQ:LPCNNASDAQ:MRKRNASDAQ:MYMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$1.54$1.48$1.12▼$3.26$15.66M2.1526,866 shs37,675 shsLPCNLipocine$3.12-1.3%$3.26$2.68▼$11.79$16.69M1.3437,366 shs12,166 shsMRKRMarker Therapeutics$1.60-5.3%$1.25$0.95▼$5.99$18.10M1.4478,721 shs169,903 shsMYMDMyMD Pharmaceuticals$0.14-10.6%$0.20$1.75▼$63.90$325K2.15134,123 shs4.02 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma0.00%-5.52%+5.48%-6.35%-45.00%LPCNLipocine-1.27%-0.64%-1.27%-6.87%-60.75%MRKRMarker Therapeutics-5.33%-9.60%+42.86%+29.55%-60.00%MYMDMyMD Pharmaceuticals-13.00%-4.01%-14.27%-58.37%-92.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOCPCocrystal Pharma2.6163 of 5 stars3.53.00.00.02.51.70.6LPCNLipocine2.1535 of 5 stars3.53.00.00.02.50.00.6MRKRMarker Therapeutics4.269 of 5 stars3.85.00.03.92.70.80.0MYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCPCocrystal Pharma 3.00Buy$7.00354.55% UpsideLPCNLipocine 3.00Buy$9.00188.46% UpsideMRKRMarker Therapeutics 3.50Strong Buy$13.17722.92% UpsideMYMDMyMD Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MYMD, MRKR, LPCN, and COCP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/29/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$8.004/1/2025MRKRMarker TherapeuticsWBB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy$12.50 ➝ $12.50(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/ALPCNLipocine$3.67M4.54N/AN/A$3.83 per share0.81MRKRMarker Therapeutics$6.59M2.75N/AN/A$1.58 per share1.01MYMDMyMD PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCPCocrystal Pharma-$17.98M-$1.57N/AN/AN/AN/A-94.62%-78.24%8/13/2025 (Estimated)LPCNLipocine-$16.35M-$1.02N/A∞N/AN/A-19.17%-17.60%8/6/2025 (Estimated)MRKRMarker Therapeutics-$8.24M-$1.33N/AN/AN/A-179.74%-89.63%-71.62%8/13/2025 (Estimated)MYMDMyMD Pharmaceuticals-$4MN/A0.00∞N/AN/A-179.05%-108.14%N/ALatest MYMD, MRKR, LPCN, and COCP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025COCPCocrystal Pharma-$0.52-$0.23+$0.29-$0.23N/AN/A5/8/2025Q4 2024LPCNLipocine-$0.35-$0.35N/A-$0.35$0.35 million$0.09 million3/31/2025Q4 2024MRKRMarker Therapeutics-$0.28-$0.42-$0.14-$0.42$5.25 million$1.22 million3/27/2025Q4 2024COCPCocrystal Pharma-$0.55-$0.32+$0.23-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOCPCocrystal PharmaN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCPCocrystal PharmaN/A7.327.32LPCNLipocineN/A12.9712.97MRKRMarker TherapeuticsN/A3.153.15MYMDMyMD PharmaceuticalsN/A0.620.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCPCocrystal Pharma6.72%LPCNLipocine9.11%MRKRMarker Therapeutics22.39%MYMDMyMD Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipCOCPCocrystal Pharma28.14%LPCNLipocine6.35%MRKRMarker Therapeutics14.50%MYMDMyMD Pharmaceuticals2.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCPCocrystal Pharma1010.17 million7.57 millionNot OptionableLPCNLipocine105.35 million5.02 millionNo DataMRKRMarker Therapeutics6011.32 million9.16 millionNot OptionableMYMDMyMD Pharmaceuticals62.37 million2.32 millionOptionableMYMD, MRKR, LPCN, and COCP HeadlinesRecent News About These CompaniesSarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightApril 24, 2025 | finance.yahoo.comMyMD-1 by TNF Pharmaceuticals for Hashimoto Thyroiditis: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comSarcopenia Market Anticipates Impressive Growth Trajectory Across 7MM During the Study Period (2020–2034) | DelveInsightSeptember 25, 2024 | finance.yahoo.comTNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related DeclineAugust 22, 2024 | finance.yahoo.comTNFA TNF Pharmaceuticals, Inc.August 16, 2024 | seekingalpha.comMyMD Pharmaceuticals is no more: Meet TNF PharmaceuticalsJuly 23, 2024 | fiercepharma.comMyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.July 22, 2024 | businesswire.comMYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q1 2024July 15, 2024 | investorplace.comMyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical OfficerJune 17, 2024 | businesswire.comMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comMYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q4 2023May 17, 2024 | investorplace.comGold prices fall as rate jitters mount ahead of Fed meetingApril 30, 2024 | msn.comMorning Bid: Dollar bulls enter the China shopApril 18, 2024 | msn.comWhy Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today?April 9, 2024 | investorplace.comRecursion Pharmaceuticals CEO sells over $1.16m in stockApril 7, 2024 | uk.investing.comExclusive-Software industry calls for more UK Government supportMarch 28, 2024 | msn.comMyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingMarch 5, 2024 | finance.yahoo.comMyMD Pharmaceuticals Stock (NASDAQ:MYMD), Short Interest ReportFebruary 22, 2024 | benzinga.comMyMD Pharmaceuticals down after announcing reverse stock splitFebruary 13, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYMD, MRKR, LPCN, and COCP Company DescriptionsCocrystal Pharma NASDAQ:COCP$1.54 0.00 (0.00%) Closing price 06/13/2025 03:55 PM EasternExtended Trading$1.57 +0.03 (+1.95%) As of 06/13/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Lipocine NASDAQ:LPCN$3.12 -0.04 (-1.27%) Closing price 06/13/2025 03:52 PM EasternExtended Trading$3.14 +0.02 (+0.61%) As of 06/13/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Marker Therapeutics NASDAQ:MRKR$1.60 -0.09 (-5.33%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.64 +0.03 (+2.19%) As of 06/13/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.MyMD Pharmaceuticals NASDAQ:MYMD$0.14 -0.02 (-10.57%) As of 06/13/2025MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
